American Association for Cancer Research

Poster Session A

POSTER SESSION A

Sunday, Jan. 19 • 5:30-7:30 p.m.

In board assignment order

  • (A01) Use of a decision aid for patients diagnosed with castration resistant prostate cancer, Randy A. Jones.
  • (A02, PR01) Monitoring copy number aberration dynamics in sequential plasma samples from castration-resistant prostate cancer (CRPC) patients, Gerhardt Attard.
  • (A03) Complementarity of genomic instability, heterogeneity, and tumor microenvironment indices for predicting prostate cancer recurrence, Paul C. Boutros.
  • (A04) The CCP score: A novel genetic test for prostate cancer prognosis, Steven Stone.
  • (A05) Sequential monitoring of circulating tumor cells (CTCs) using the Epic Sciences platform in castration-resistant prostate cancer (CRPC) patients treated with AR targeting therapeutics (ATT), Roberta Ferraldeschi.
  • (A06) Evaluation of a Genomic Classifier (Decipher) in subsets of primary tumors with common prostate cancer genomic alterations, Mohammed Alshalafa.
  • (A07) Integration of the Decipher genomic classifier with SChLAP1 long noncoding RNA for improved prediction of metastasis post radical prostatectomy, Felix Feng.
  • (A08) Validation of a genomic classifier for predicting clinical progression following postoperative radiation therapy in high-risk prostate cancer, Robert B. Den.
  • (A09) Improving risk stratification for prostate cancer using the long noncoding RNA SChLAP1, a novel biomarker of aggressive disease, Felix Y. Feng.
  • (A10) MicroRNA profiles as predictors of aggressive prostate cancer, Mireia Olivan.
  • (A11, PR02) Frequency and characterization of circulating tumor cell (CTC) populations in metastatic castration-resistant prostate cancer (mCRPC), Ryan Dittamore.
  • (A12) Genetic variation in the IL-6 response element of SPINK1 promoter and prostate cancer in men of African descent, Danyelle Winchester.
  • (A13) Dietary and lifestyle factors and risk of progression in contemporary active surveillance patients, Bruce J. Trock.
  • (A14) Modification of IGF/insulin signaling in prostate cancer survival by TMPRSS2:ERG fusion, Thomas U. Ahearn.
  • (A15, PR03) Development and validation of a lifestyle score for prevention of lethal prostate cancer, Stacey A. Kenfield.
  • (A16) Meat, fish, poultry, and egg intake at diagnosis and risk of prostate cancer progression, Kathryn M. Wilson.
  • (A17) BRCA1single nucleotide polymorphisms (SNPs) may help identify patients at risk for lethal prostate cancer or recurrence after treatment with radiation therapy, Irene Shui.
  • (A18) Association of obesity and diabetes with clinical characteristics and recurrence from prostate cancer in an ethnically-diverse population, Ilir Agalliu.
  • (A19) The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer, Rebecca E. Graff.
  • (A20) A novel gene expression signature predictive of clinical recurrence after radical prostatectomy in early-stage prostate cancer patients, Ahva Shahabi.
  • (A21, PR04) Urinary melatonin levels, sleep disruption, and risk of prostate cancer, Sarah C. Markt.
  • (A22) Obesity, IGF-1 receptor, and prostate cancer survival, Ericka Noonan.
  • (A23) Physical activity and tumor vessel morphology among men with prostate cancer, Erin Van Blarigan.
  • (A24) The impact of body mass index on treatment recommendations for patients with low-intermediate risk prostate cancer. Kosj Yamoah.
  • (A25) Molecular differences in transition zone and peripheral zone tumors, Jennifer A. Sinnott.
  • (A26) Immediate vs. delayed initiation of androgen deprivation therapy on PSA-relapsed prostate cancer, Xabier Garcia-Albeniz.
  • (A27) Prevalence of undetected prostate cancer: Implications for epidemiology in the PSA-Era, Jaquelyn L. Jahn.
  • (A28) Nonseasonal-SAD and APO E4 as risk factors for prostate cancer, Tim R. D. Oliver.
  • (A29) Inhibition of lactate production for modulating prostate cancer aggressiveness and metastatic potential, Pankaj Seth.
  • (A30) CYP3A5 regulates prostate cancer growth by facilitating nuclear translocation of AR, Ranjana Mitra.
  • (A31) YAP1 Is a key component of the AR signaling complexes in prostate cancer cells, Bekir Cinar.
  • (A32) Androgen receptor non-nuclear regulation of prostate tumor cell invasion through Matriptase and Src signaling, Jelani C. Zarif.
  • (A33) Influence of tumor microenvironment on the expression of tumor metastasis suppressor KISS1 in prostate cancer, Honghe Wang.
  • (A35) New insights into the regulation of the androgen receptor by PMEPA1/NEDD4-1 in prostate cancer, Hua Li.
  • (A36) Two independent functional screens identify miRNAs that regulate the AR signaling axis in prostate cancer, Binod Kumar.
  • (A37) Evaluation of ERG responsive proteome in prostate cancer cells, Shyh-Han Tan.
  • (A38) NOTCH transcription factors as common targets of ERG in diverse tumor cell types, Ahmed A. Mohamed.
  • (A39) Functional characterization of androgen receptor ubiquitylation sites in prostate cancer cells, Ziyang Yu.
  • (A40) Expression of ING3 associated with prostate cancer progression, Amal Almami.
  • (A41) SNPs that modulate the TMPRSS2 androgen responsiveness, Frank Claessens.
  • (A42) ADRB2 down-regulation affects glucuronidation activity and improves androgen receptor sensitivity in LNCaP cells, Peder Rustøen Braadland.
  • (A43) Metformin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor, Kato Haruo.
  • (A44) Analysis of domains required for the oncogenic function of ETS transcription factors in prostate cells, Vivekananda Kedage.
  • (A45) Monitoring androgen receptor dynamics at the single cell level, Katherin Patsch.
  • (A46) Loss-of-function mutations in RFC1 and TET1 in primary prostate cancer, Lien Spans.
  • (A47) Insulin increases migration and invasion in androgen deprived prostate cancer cells, Jennifer H. Gunter.
  • (A48) PTEN loss together with ERG overexpression correlates with shorter survival after radical prostatectomy, Andrew Erickson.
  • (A49) p38-MAPK regulation of Notch signaling is required for normal prostate epithelial differentiation, Sander B. Frank.
  • (A50) Prostate cancer genetic-susceptibility locus on chromosome 20q13 is androgen receptor-regulated and amplified in metastatic tumors, David P. Labbé.
  • (A51) AXIN2 predicts prostate cancer recurrence and promotes an invasive, cancer stem-like phenotype, Brian Hu.
  • (A52) HDAC inhibition sensitizes prostate cancer cells to PARP inhibitor through downregulation of DNA repair proteins, Olivia S. Chao.
  • (A53) Global transcriptome sequencing of ethnically diverse formalin-fixed patient samples in prostate cancer identifies biomarkers of recurrence, Carlos S. Moreno.
  • (A54, PR06) Coordinate induction of autophagy and apoptosis by wildtype p53 in prostate cancer cells, Chris Albanese.
  • (A55) Tumor suppressive roles of FoxA1 in castration-resistant prostate cancer, Jindan Yu.
  • (A56, PR07) Patient-specific kinase activation patterns in lethal metastatic castration resistant prostate cancer, Justin M. Drake.
  • (A57) Modeling genetic changes of LnCAP in the mouse: The role of Abi1 in prostate tumor progression in the absence of PTEN, Leszek Kotula.
  • (A58) Integrated analysis of epigenomic and genomic changes regulated by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer, Nicole M.A. White-Habeeb.
  • (A59) Androgen receptor directly suppresses the expression of a subset of genes mediating DNA synthesis, Changmeng Cai.
  • (A60) A novel metastatic mouse model of advanced prostate cancer driven by the c-Myc and KLF6-SV1 oncogenes, Sudeh Izadmehr.
  • (A61) Targeting MYC-driven growth and proliferation in prostate cancer, Luc Furic.
  • (A62) Role of hepatoma up-regulated protein (HURP) in prostate cancer tumorigenesis and resistance to therapy, Christian R. Gomez.
  • (A63) SOCS3 deficiency in myeloid cells promotes prostate tumor development, Etty (Tika) N. Benveniste.
  • (A64) Combining ex vivo culture and tumorgraft models for the benign and malignant human prostate, Sophia L. Maund.
  • (A65) Inhibition of radiation induced CXCL8 signaling sensitizes PTEN-deficient prostate carcinoma tumors to ionizing radiation, David J. Waugh.
  • (A66) Genetically modifying Apc and Smad4 in the murine prostate incudes HGPIN and carcinoma, Kenneth C. Valkenburg.
  • (A67) Novel animal models to study dormant prostate and prostate cancer cells, Dingxiao Zhang.
  • (A68) Rad9 controls integrin beta1 expression and mediates radiosensitivity of prostate cancer cells, Constantinos G. Broustas.
  • (A69) Lyn kinase induces mesenchymal phenotype by stabilizing Slug, Daksh Thaper.
  • (A70) The miR-409-5p in the imprinted and developmentally regulated DLK1-DIO3 cluster promotes tumorigenesis, epithelial to mesenchymal transition and bone metastasis in prostate cancer, Murali Gururajan.
  • (A71) Persistent androgen ablation promotes enhanced neuroendocrine features in Pten-deficient prostate cancer, David J. Mulholland.
  • (A72) Cabozantinib attenuates CXCL8-driven macrophage-dependent migration and invasion of PTEN-deficient prostate cancer, David J. Waugh.